SCRI-E2CAR_EGFRtv1/UB-TT170 / Seattle Children’s Therapeutics, Umoja Biopharma - LARVOL DELTA

ENLIGHTen-01: A Phase I Feasibility and Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells in Combination with Parenterally Administered Folate-Fluorescein (UB-TT170) for Osteogenic Sarcoma (clinicaltrials.gov) - P1 | N=21 | Active, not recruiting | Sponsor: Seattle Children's Hospital | Recruiting ➔ Active, not recruiting

CAR T-Cell Therapy • Combination therapy • Enrollment closed • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire) - "Umoja Biopharma...announced that Umoja will present two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)....Umoja’s poster presentations will focus on preclinical data of UB-VV400, an off-the-shelf, multidomain fusion (MDF) protein surface engineered lentiviral vector designed to generate CD22-directed CAR T cells in vivo without requiring lymphodepleting chemotherapy, as well as the company’s RACR-induced cytotoxic lymphocytes (iCIL) platform and its potential for increased production and persistence of CAR T cells....In addition to Umoja’s poster presentations, Seattle Children’s Therapeutics, Umoja’s collaboration partner will be presenting early experience data from the ENLIGHTen-01 trial of UB-TT170."

P1 data • Preclinical • Osteosarcoma

ENLIGHten-01: A phase 1 study of fluorescein-specific (FITC-E2)-CAR T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma. (ASCO 2023) - P1 | "The trial remains open to enrollment. Clinical trial information: NCT05312411."

CAR T-Cell Therapy • Combination therapy • IO biomarker • P1 data • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Seattle Children's Hospital | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Combination therapy • Enrollment open • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells (GlobeNewswire) - "Umoja Biopharma, Inc....announced today the Seattle Children’s activation of the Phase 1 ENLIGHTen clinical trial in patients with osteosarcoma to assess the safety and tolerability of autologous 'universal' CAR T cells when administered with UB-TT170, the Company’s proprietary small molecule fluorescein tag. This follows the recent clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for UB-TT170. The trial is being conducted in partnership with Seattle Children’s Therapeutics, a venture at Seattle Children's, bringing cutting edge, curative technologies and therapies to defeat pediatric cancer and other diseases that impact children."

Trial status • Oncology • Osteosarcoma • Sarcoma • Solid Tumor